Clinical Trial

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Name: Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease — clinical trial record (NCT06314698)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Record status

This record was last updated March 18, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.

Summary

The purpose of this study is to determine if narlumosbart is non-inferior to denosumab in the treatment of bone diseases from multiple myeloma (MM).

Trial Details

NCT Number	NCT06314698
Lead Sponsor	RenJi Hospital Collaborators: Shanghai JMT-Bio Inc.
Conditions	Multiple Myeloma, Bone Diseases
Enrollment	478 participants
Start Date	2024-04-01
Primary Completion	2024-12-31 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2024-03-18